Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Center, Open-Label, Randomized Phase 2 Study of Copper Cu 64 PSMA I&T Injection in Patients With Histologically Proven Metastatic Prostate Cancer

NCT05653856 is registered in ClinicalTrials.gov with Curium US LLC as lead sponsor.

NCT NCT05653856
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05653856 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Center, Open-Label, Randomized Phase 2 Study of Copper Cu 64 PSMA I&T Injection in Patients With Histologically Proven Metastatic Prostate Cancer
Lead sponsor
Curium US LLC
Phase
Phase 2
Overall status
Completed
Start date
December 5, 2022
Completion date
May 17, 2023
Enrollment
26 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

metastasis from malignant tumor of prostate (disorder)